Despite early indicators of artemisinin resistance in Rwanda, ACTs continue to cure malaria
Programme offers a collaborative platform where participants can freely share data and ideas to accelerate innovation.
of injectable artesunate for severe malaria delivered since 2010, saving the lives of over 1m additional vulnerable children compared with quinine treatment
shipped free of charge to scientists around the world to boost drug discovery for neglected diseases
working to help defeat malaria – part of an overall network of 400 partners in 50 countries
160 different drugs or compounds with known or predicted activity against SARS-COV2 and other coronaviruses, available free of charge.
The MMV at a glance highlights our unique partnership model, the growth of our portfolio and the increasing impact of our access work.
Next-generation researchers in malaria and other neglected diseases discuss their work and aspirations.